ArticleBrain communications2025
Onset ages of cerebrovascular disease and amyloid and effects on cognition in risk-enriched cohorts.
Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.Nature medicine · 2026Article
- Neurobiological correlates of longitudinal grey matter volume changes in preclinical Alzheimer's disease.medRxiv : the preprint server for health sciences · 2025Article
- Tau mediates the impact of amyloid and vascular disease burden on the trajectory of clinical symptoms.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
The temporal relationship between cerebrovascular disease (V), indicated by white matter hyperintensities, and beta-amyloid (A) in Alzheimer's disease remains unclear, prompting speculation about their potential interdependence. Longitudinal data were employed to estimate onset ages and corresponding disease chronicity for A and V (where disease chronicity is calculated as age at measurement minus estimated age of biomarker abnormality onset). In a large, predominantly cognitively unimpaired dataset (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.